Male Menopause Syndrome Medical Services in China

Male Andropause Syndrome, also known as Late-Onset Hypogonadism (LOH), is a clinical condition characterized by progressive decline in serum testosterone levels—typically beginning after age 40—accompanied by physiological and psychological symptoms including fatigue, decreased libido, erectile dysfunction, mood lability, reduced muscle mass, increased adiposity, and impaired cognitive concentration. Unlike female menopause, andropause manifests gradually and variably across individuals; diagnosis requires correlation of consistent symptomatology with confirmed low total and/or free testosterone levels on repeated morning blood tests, excluding secondary causes such as pituitary disorders, chronic illness, or medication effects. Management emphasizes individualized hormone replacement therapy (HRT) alongside lifestyle optimization, metabolic assessment, and cardiovascular risk stratification to mitigate potential adverse effects.

China offers distinct advantages for international patients seeking evidence-based andropause care. Leading urology-andrology centers—many affiliated with top-tier academic hospitals—employ board-certified specialists trained in endocrine urology and sexual medicine, utilizing advanced diagnostic platforms including LC-MS/MS testosterone assays, DEXA scanning, and validated symptom scoring tools (e.g., ADAM, AMS). Robust clinical experience is reflected in published outcomes: over 85% of patients report significant improvement in sexual function and quality-of-life metrics within 3–6 months of protocol-driven HRT. Treatment costs—including diagnostics, consultation, and 12-month HRT regimens—are typically 40–60% lower than in the US, UK, or Germany, without compromising safety or efficacy standards. As a dedicated medical tourism agency, we facilitate seamless access to these services: coordinating appointments with certified andrologists, verifying hospital accreditation (JCI or CNAS), providing itemized, upfront pricing in USD/EUR, arranging visa support, translation, accommodation, and post-treatment follow-up—all tailored to international patient needs.

Treatment Options & Itemized Cost Breakdown: Male Andropause Syndrome (Androgen Deficiency in Aging Males)

Non-Surgical / Conservative / Medication Options

*Target Criteria:* Confirmed total testosterone <300 ng/dL + consistent symptoms (fatigue, low libido, depression, metabolic dysfunction) after ruling out secondary causes (pituitary disease, chronic illness).

• •Baseline Diagnostic Workup

- Serum total testosterone (morning draw), free testosterone (calculated), LH, FSH, prolactin, CBC, liver/kidney function, lipid panel, PSA (≥40 years): $125–$180

• •Testosterone Replacement Therapy (TRT)

- *Gel (1% testosterone)*: $220–$310/month (5–10 g/day; requires daily application, skin transfer risk)

- *Injectable (testosterone cypionate/enanthate)*: $145–$210/month (100–200 mg/week; includes syringes, alcohol swabs) - *Long-acting injectable (testosterone undecanoate)*: $390–$520 per injection (750 mg every 10–14 weeks; includes administration fee)

• •Adjunctive Therapies

- Lifestyle intervention (structured exercise/nutrition counseling, 6-session program): $280–$420

- Selective serotonin reuptake inhibitor (e.g., escitalopram) for comorbid depression: $25–$45/month

Surgical / Procedural / Interventional Options

*Eligibility Criteria:* TRT failure or contraindication (e.g., severe untreated sleep apnea, hematocrit >52%, active prostate cancer), plus documented hypogonadism with pituitary MRI-confirmed microadenoma or testicular failure requiring definitive management.

• •Pituitary Microsurgery (Transnasal Endoscopic)

- Preoperative: Pituitary MRI + dynamic hormone testing (ACTH/cortisol, GH/IGF-1, TSH): $480–$650

- Procedure (including anesthesia, OR time, neurosurgeon fee): $4,200–$6,800

• •Testicular Biopsy (Diagnostic)

- Indicated for suspected primary testicular failure with discordant LH/testosterone: $320–$460 (includes histopathology)

Special / Complex Condition Management

• •Severe Anemia + Hypogonadism (Hematocrit <30%): Erythropoietin-stimulating agent + TRT titration: $720–$1,150/month
• •Metabolic Syndrome Comorbidity (T2DM, NAFLD): Integrated endocrinology-andrology care (quarterly visits, HbA1c, liver elastography, dual-energy X-ray absorptiometry): $1,350–$1,980/year

Quick Selection Guide

• •Age <50, Mild Symptoms, Budget-Conscious: Start with diagnostic workup ($125–$180) → TRT gel ($220/month); avoid surgery unless MRI-confirmed adenoma.
• •Age 55–70, Moderate–Severe Symptoms, Comorbid Obesity/T2DM: TRT injection ($145/month) + integrated metabolic care ($1,350/year); prioritize lifestyle intervention ($280).
• •Age ≥70, TRT Failure, Elevated Hematocrit/PSA Concerns: Diagnostic testicular biopsy ($320) → referral to endocrinology for non-testosterone anabolic agents (oxandrolone: $380/month) or dose-adjusted TRT under hematology co-management.
• •Any Age with Pituitary Mass on MRI: Proceed directly to preoperative testing ($480–$650) → transnasal microsurgery ($4,200–$6,800); avoid TRT until post-op hormonal recovery assessment.